Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dan Tang

Internal Medicine Cambridge, MA Medical Doctor

NPI 1992990394 CMS profile 226473

330 Mount Auburn St, Ste 1, Cambridge, MA 02138

Open in the dashboard

General payments

$5,090

249 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dan Tang of Cambridge, MA is reported in the CMS Open Payments database as having received $5,090 across 249 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $78 3
2024 General $1,034 46
2023 General $1,014 49
2022 General $805 40
2021 General $623 31
2020 General $525 26
2019 General $1,011 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dan Tang
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Dan Tang were reported at $78. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Dan Tang Internal Medicine median Middle half National median
2019 $1,011 $159 $48–$570 $163
2020 $525 $119 $33–$402 $114
2021 $623 $135 $37–$521 $132
2022 $805 $141 $42–$496 $149
2023 $1,014 $149 $45–$519 $160
2024 $1,034 $154 $47–$537 $164
2025 $78 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $883 45 payments
  2. Novo Nordisk Inc $520 26 payments
  3. Abbott Laboratories $452 20 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $305 13 payments
  5. AstraZeneca Pharmaceuticals LP $285 13 payments
  6. Sanofi-Aventis U.S. LLC $283 13 payments
  7. Antares Pharma, Inc. $246 12 payments
  8. Xeris Pharmaceuticals, Inc. $231 12 payments
  9. Mannkind Corporation $209 9 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $208 9 payments
  11. Other $1,469 77 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,050 246 payments
  2. Education $40 3 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $490 24 payments
  2. Ozempic $361 18 payments
  3. JARDIANCE Diabetes $305 13 payments
  4. FreeStyle Libre 3 $275 11 payments
  5. RYBELSUS $265 14 payments
  6. FARXIGA $241 11 payments
  7. TRADJENTA $233 10 payments
  8. AFREZZA $209 9 payments
  9. XYOSTED $184 9 payments
  10. Kerendia $182 8 payments
  11. Other $4,043 208 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 61 drugs

Part D claims

4,947

Median for Endocrinology: 1,959

Drug cost

$2,270,395

Median for Endocrinology: $890,201

Branded share of claims

77.1%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 367 $421,984
Ozempic Semaglutide Brand 274 $329,257
Jardiance Empagliflozin Brand 308 $287,046
Tresiba Flextouch U-200 Insulin Degludec Brand 103 $105,374
Fiasp Flextouch Insulin Aspart (Niacinamide) Brand 116 $87,943
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 135 $85,783
Farxiga Dapagliflozin Propanediol Brand 108 $85,208
Mounjaro Tirzepatide Brand 69 $79,422
Rybelsus Semaglutide Brand 41 $65,105
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 50 $60,856

The 10 drugs with the highest cost, of 61 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$69,726

Medicare's payments for the services billed

Medicare patients

428

Average age 72

Services billed

876

285 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 62%
Arthritis 43%
Chronic kidney disease 34%
Depression 32%
Ischemic heart disease 27%
Osteoporosis 23%
Heart failure 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $159
$159 308 —
RECORLEV
  • Xeris Pharmaceuticals, Inc. $65
$65 — —
Korlym
  • Corcept Therapeutics $55
$55 — —
MOUNJARO
  • Lilly USA, LLC $46
$46 69 —
JATENZO
  • TOLMAR, INC. $46
$46 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

249 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record